Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin in LAM and TSC
NCT02061397Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Mar 2014
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of simvastatin in lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC), sponsored by University of Pennsylvania. Primary endpoint: Safety of Simvastatin in the Treatment of LAM-S and LAM-TS Patients at 5 months. Started Mar 2014; status: completed.
02
Drugs
simvastatin
03
Conditions
lymphangioleiomyomatosis (LAM)tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on NCT02061397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061397.